HUP0301390A2 - Valzartánt tartalmazó orális gyógyászati készítmény - Google Patents

Valzartánt tartalmazó orális gyógyászati készítmény

Info

Publication number
HUP0301390A2
HUP0301390A2 HU0301390A HUP0301390A HUP0301390A2 HU P0301390 A2 HUP0301390 A2 HU P0301390A2 HU 0301390 A HU0301390 A HU 0301390A HU P0301390 A HUP0301390 A HU P0301390A HU P0301390 A2 HUP0301390 A2 HU P0301390A2
Authority
HU
Hungary
Prior art keywords
valsartan
pharmaceutical composition
composition containing
oral pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
HU0301390A
Other languages
English (en)
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0301390A2 publication Critical patent/HUP0301390A2/hu
Publication of HUP0301390A3 publication Critical patent/HUP0301390A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A találmány orális szilárd gyógyászati készítményre vonatkozik, amelyvalzartánnak vagy gyógyászatilag elfogadható sójának vagy hidrátjánakgyógyászatilag hatásos mennyiségét legalább egy gyógyászatilagelfogadható segédanyaggal együtt tartalmazza, és amelynek abiohasznosíthatósága a valzartán kapszuláénál átlagosan legalább 1,2-szer nagyobb. A javult biohasznosíthatóság más előnyök mellett kisebbméretű, illetve hatóanyag-tartalmú készítmény, például tablettaelőállítását teszi lehetővé, amelyet a betegek jobban elviselnek. Ó
HU0301390A 2000-06-22 2001-06-20 Oral pharmaceutical composition containing valsartan HUP0301390A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (2)

Publication Number Publication Date
HUP0301390A2 true HUP0301390A2 (hu) 2003-11-28
HUP0301390A3 HUP0301390A3 (en) 2005-04-28

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301390A HUP0301390A3 (en) 2000-06-22 2001-06-20 Oral pharmaceutical composition containing valsartan

Country Status (21)

Country Link
EP (2) EP2072049A3 (hu)
JP (3) JP2003535895A (hu)
KR (2) KR100659644B1 (hu)
CN (2) CN1221256C (hu)
AU (2) AU2001285768B2 (hu)
BR (1) BR0111868A (hu)
CA (1) CA2411882C (hu)
CZ (1) CZ20024180A3 (hu)
EC (1) ECSP024389A (hu)
HK (2) HK1052868A1 (hu)
HU (1) HUP0301390A3 (hu)
IL (2) IL153428A0 (hu)
MX (1) MXPA02012683A (hu)
NO (1) NO20026123L (hu)
NZ (2) NZ522953A (hu)
PL (1) PL358290A1 (hu)
RU (1) RU2333757C2 (hu)
SG (1) SG162605A1 (hu)
SK (1) SK18062002A3 (hu)
WO (1) WO2001097805A2 (hu)
ZA (1) ZA200210359B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
EP1467728B1 (en) * 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1833464A1 (en) 2004-12-24 2007-09-19 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
CA2701695A1 (en) 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag At1 rezeptor antagonist zur anregung von apoptosis
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
PL365696A1 (en) * 2000-04-12 2005-01-10 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
KR100525341B1 (ko) 2005-11-02
KR100659644B1 (ko) 2006-12-21
HK1052868A1 (zh) 2003-10-03
CN1679551A (zh) 2005-10-12
CA2411882A1 (en) 2001-12-27
KR20030019450A (ko) 2003-03-06
ZA200210359B (en) 2003-11-13
IL153428A (en) 2013-12-31
EP2072049A3 (en) 2009-12-30
JP2003535895A (ja) 2003-12-02
NZ540748A (en) 2007-04-27
NO20026123D0 (no) 2002-12-19
WO2001097805A2 (en) 2001-12-27
BR0111868A (pt) 2003-07-01
IL153428A0 (en) 2003-07-06
SK18062002A3 (sk) 2003-07-01
HK1083452A1 (en) 2006-07-07
NO20026123L (no) 2003-02-18
CN1437469A (zh) 2003-08-20
EP1296677A2 (en) 2003-04-02
CN1221256C (zh) 2005-10-05
JP2007091758A (ja) 2007-04-12
HUP0301390A3 (en) 2005-04-28
JP2012211200A (ja) 2012-11-01
CA2411882C (en) 2011-09-06
AU8576801A (en) 2002-01-02
MXPA02012683A (es) 2003-04-25
PL358290A1 (en) 2004-08-09
NZ522953A (en) 2005-10-28
WO2001097805A3 (en) 2002-08-29
CZ20024180A3 (cs) 2003-04-16
CN100450478C (zh) 2009-01-14
RU2333757C2 (ru) 2008-09-20
KR20050085978A (ko) 2005-08-29
AU2001285768B2 (en) 2005-03-10
SG162605A1 (en) 2010-07-29
EP2072049A2 (en) 2009-06-24
ECSP024389A (es) 2003-02-06

Similar Documents

Publication Publication Date Title
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
HUP0203176A2 (hu) Szimetikont tartalmazó orális, szilárd adagolási forma
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
HUP0103108A2 (hu) Formoterolt és budesonidot tartalmazó készítmény alkalmazása asztma akut állapotának megelőzésére
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
BG105173A (en) Novel salt form of pantoprazole
HUP0204451A2 (hu) Nimesulidot tartalmazó szabályozott hatóanyag-leadású készítmények
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EP0749308A1 (en) Film coated tablet of paracetamol and domperidone
HUP0401429A2 (hu) Lumirakoxibot tartalmazó gyógyszerkészítmény
HUP0400127A2 (hu) Paracetamolt tartalmazó lenyelhető tabletta
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
HUP0103071A2 (hu) Citalopramot tartalmazó gyógyászati készítmény

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal